Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q86Y91
UPID:
KI18B_HUMAN
Alternative names:
-
Alternative UPACC:
Q86Y91; A0A0C4DGP2; A0A0C4DGP5; A6NJI2; B7ZM49; B9EGM8; D5L6I1
Background:
Kinesin-like protein KIF18B, in complex with KIF2C, plays a pivotal role in mitotic cell division by depolymerizing microtubules at their plus ends. This action is crucial for the proper segregation of chromosomes. KIF18B's interaction with MAPRE1 and its transportation along microtubules underscore its significance in cellular dynamics and division.
Therapeutic significance:
Understanding the role of Kinesin-like protein KIF18B could open doors to potential therapeutic strategies. Its critical function in cell division highlights its potential as a target in cancer therapy, where uncontrolled cell division is a hallmark.